Ali Urman is a Genomics Analyst and investor, passionate about immunotherapy, gene editing, stem cell therapy, AI, space medicine and public health.
Ali joined ARK as an Analyst on the Genomic Revolution strategy in February 2020. She focuses on gene editing, stem cell and novel immunotherapy technologies.
Prior to ARK, Ali conducted clinical cancer research at the Memorial Sloan Kettering Cancer Center and the Montefiore Medical Center; and was a Senior Research Program Manager at IBM Watson Health. Ali incorporated her own consulting firm in 2018.
Ali holds numerous board and advisory positions, including a Board Member of Cure Rare Disease, an Industry Advisor for the Sanford School of Medicine’s SPARK program, No Patient Left Behind, Sortium, and The Innovation Foundation.
Ali has published over 25 articles spanning cancer research, AI and space medicine. She has three filed patents and received the Manager’s Choice Award in 2017 and 2018, and the Rookie of the Year Award in 2017 from IBM Watson Health.
Ali has a Bachelor of Arts from McGill University and a Masters in Epidemiology and Community Health from New York Medical College. She has additional training from the MIT Labs in Human-Computer Interaction for User Experience Design.
Ali has appeared on CNBC, Bloomberg and TD Ameritrade. She has been quoted and her research has been featured in Fortune, Business Insider, Nasdaq.com, Advisor Analyst, OPTO, ETF Trends, among other publications. She has been a featured speaker at the Forbes and APSG conferences and guest lecturer at the University of Maryland and New York University.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
© CURE RARE DISEASE. ALL RIGHTS RESERVED.
.png)
© CURE RARE DISEASE.ALL RIGHTS RESERVED.
